Rosen says GeneDx investors can seek lead-plaintiff role in securities suit
Rosen Law Firm says investors who bought GeneDx Holdings Corp. common stock during a defined class period may seek to join a securities fraud class action before an Aug. 3 deadline.
Rosen Law Firm says investors who bought GeneDx Holdings Corp. common stock during a defined class period may seek to join a securities fraud class action before an Aug. 3 deadline.
Rosen Law Firm said on Aug. 1 that purchasers of GeneDx Holdings Corp. common stock during a class period running from April 16, 2025, through May 4, 2026, may be able to seek compensation in a securities fraud class action that has already been filed.
The notice says investors who want to serve as lead plaintiff must move the court by Aug. 3, 2026. It also says no class has been certified, and investors may retain counsel, choose their own lawyer or remain absent class members for now.
The notice centers on allegations that GeneDx made misleading statements about Fabric and the effect of the acquisition on GeneDx’s business. Rosen’s summary says the case concerns claims about the impact of Fabric on GeneDx’s financials and operations, including whether the deal would create efficiencies.
According to the notice, one statement said there was room to reduce cost of goods sold by combining capabilities between GeneDx and Fabric to optimize dry lab processes. The notice says those and similar statements were false.
Rosen’s summary also alleges that defendants knew of, or recklessly disregarded, significant problems in Fabric’s viability that would hurt GeneDx’s overall business and operations. The notice says investors suffered damages when the true details entered the market.
The notice describes Rosen as a global investor rights law firm focused on securities class actions and shareholder derivative litigation. It says investors who bought during the class period may be eligible for compensation through a contingency-fee arrangement with no out-of-pocket fees or costs.
The notice also directs investors to a website or to contact Phillip Kim, Esq., for more information on joining the case.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.